Search by Drug Name or NDC
NDC 23155-0771-41 foscarnet sodium 24 mg/mL Details
foscarnet sodium 24 mg/mL
foscarnet sodium is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.. The primary component is FOSCARNET SODIUM.
MedlinePlus Drug Summary
Foscarnet injection is used alone or with ganciclovir (Cytovene) to treat cytomegalovirus (CMV) retinitis (an eye infection that can cause blindness) in people who have human immunodeficiency virus (HIV) infection. Foscarnet injection is also used to treat herpes simplex virus (HSV) infections of the skin and mucus membranes (mouth, anus) in people whose immune system is not working normally and when treatment with acyclovir did not help. Foscarnet is in a class of medications called antivirals. It works by slowing the growth of CMV and HSV. Foscarnet controls CMV retinitis and HSV infections of the skin and mucus membranes but does not cure these infections.
Related Packages: 23155-0771-41Last Updated: 03/24/2024
MedLinePlus Full Drug Details: Foscarnet Injection
Product Information
| NDC | 23155-0771 |
|---|---|
| Product ID | 23155-771_049dbba3-cc3f-41a9-8a5f-db7444a506b2 |
| Associated GPIs | |
| GCN Sequence Number | 016348 |
| GCN Sequence Number Description | foscarnet sodium INFUS. BTL 24 MG/ML INTRAVEN |
| HIC3 | W5A |
| HIC3 Description | ANTIVIRALS, GENERAL |
| GCN | 32041 |
| HICL Sequence Number | 013221 |
| HICL Sequence Number Description | FOSCARNET SODIUM |
| Brand/Generic | Generic |
| Proprietary Name | foscarnet sodium |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | foscarnet sodium |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 24 |
| Active Ingredient Units | mg/mL |
| Substance Name | FOSCARNET SODIUM |
| Labeler Name | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. |
| Pharmaceutical Class | Chelating Activity [MoA], DNA Polymerase Inhibitors [MoA], Pyrophosphate Analog DNA Polymerase Inhibitor [EPC], Pyrophosphate Analog [EXT] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA213807 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 23155-0771-41 (23155077141)
| NDC Package Code | 23155-771-41 |
|---|---|
| Billing NDC | 23155077141 |
| Package | 10 CARTON in 1 CARTON (23155-771-41) / 1 BOTTLE in 1 CARTON (23155-771-31) / 250 mL in 1 BOTTLE |
| Marketing Start Date | 2023-06-05 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |